Oxymetazoline Cream Formulation for High-Ionic-Strength Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Creating a stable, efficacious, and cosmetically elegant cream formulation of oxymetazoline for treating rosacea is challenging due to its high ionic strength, which affects skin tolerance and efficacy.
Innovation Solution
A unique cream formulation with a complex oil phase and high concentration of oxymetazoline, maintaining minimum viscosity to support stability and increased flux, overcoming the challenges of high ionic strength.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high concentration of oxymetazoline is used to improve efficacy, then therapeutic effect is enhanced, but formulation stability deteriorates due to high ionic strength
Solution Approach 1:
The patent introduces a complex oil phase composition as an intermediary medium that can accommodate high concentrations of oxymetazoline hydrochloride while maintaining formulation stability. The oil phase acts as a mediator between the ionic active ingredient and the aqueous environment, preventing premature dissociation and maintaining drug efficacy without compromising stability.
Solution Approach 2:
The invention employs a composite cream formulation combining multiple components including a complex oil phase (comprising multiple triglycerides, fatty acids, and their esters), water-soluble polymers, and oxymetazoline hydrochloride. This composite structure allows the formulation to maintain both high drug concentration for efficacy and structural stability through the synergistic interaction of different material types.
2Reliability
If high ionic strength formulation is used to increase oxymetazoline concentration, then therapeutic effect is improved, but skin tolerance deteriorates
Solution Approach 1:
The complex oil phase serves as a protective intermediary layer that delivers oxymetazoline to the skin while buffering the high ionic strength effects. This intermediary medium reduces direct contact between the ionic drug and skin proteins, thereby minimizing irritation while maintaining therapeutic efficacy through controlled drug release.
Solution Approach 2:
The patent modifies the physical-chemical parameters of the formulation by adjusting the oil phase composition, polymer concentration, and pH balance to accommodate high ionic strength while reducing skin penetration of irritants. These parameter changes allow the formulation to maintain high drug concentration without proportionally increasing skin tolerance issues.
3Stability of the object's composition
If complex oil phase is used to maintain formulation stability, then physical stability is improved, but manufacturing complexity increases
Solution Approach 1:
The complex oil phase is segmented into specific functional components: triglycerides for emulsification, fatty acids for stability, and specific ester compounds for texture and compatibility. This segmentation allows each component to be optimized independently and simplifies the manufacturing process by enabling separate purification and quality control steps for each ingredient category.
Solution Approach 2:
The patent establishes specific parameter ranges for the oil phase composition (e.g., triglyceride content of 40-70%, fatty acid composition ratios, viscosity parameters) that balance formulation stability with manufacturability. These parameter specifications provide clear manufacturing guidelines and quality control criteria, reducing the complexity of production while maintaining the desired stable formulation.
Data Source
AI summary
The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient.